Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
GSK: Consumer Healthcare sales grew 5% to $1.5 bil. during the second quarter of 2006, GlaxoSmithKline announces July 26. Revenues in European and International markets increased 8% and 9%, respectively, while sales in North America declined 3%, which reflected, in part, the impact of divesting several dermatological creams in 2005. OTC drug sales grew 3% to $674 mil. during the quarter as a result of sales growth in analgesics (13%), smoking cessation products (8%) and respiratory tract medicines (10%). Oral care sales grew 7% to $467 mil. due to a 25% revenue growth for Sensodyne, which offset the 5% reduction in Aquafresh sales...
You may also be interested in...
Claritin-D “Staying Tough” Behind The Counter With Pseudoephedrine
New ads for Schering-Plough's Claritin-D aim to position the manufacturer as taking a stand by declining to join the ranks of OTC manufacturers who are reformulating their pseudoephedrine-containing products with phenylephrine
Claritin-D “Staying Tough” Behind The Counter With Pseudoephedrine
New ads for Schering-Plough's Claritin-D aim to position the manufacturer as taking a stand by declining to join the ranks of OTC manufacturers who are reformulating their pseudoephedrine-containing products with phenylephrine
Claritin-D “Staying Tough” Behind The Counter With Pseudoephedrine
New ads for Schering-Plough's Claritin-D aim to position the manufacturer as taking a stand by declining to join the ranks of OTC manufacturers who are reformulating their pseudoephedrine-containing products with phenylephrine